A New York State panel has recommended that officials seek a supplemental Medicaid rebate for a pricey rare disease drug sold by Biogen (BIIB), marking only the third time such a move was proposed because a medicine may cause the state Medicaid program to exceed a cap on drug spending.

In a 14-to-0 vote last Thursday, the state’s Drug Utilization Review panel agreed that a rebate should be pursued for Spinraza, which is used to treat muscular spinal atrophy, an often-fatal genetic disease affecting muscle strength and movement. In its deadliest form, referred to as Type 1, the disease causes children to die by the time they turn 2 years old.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy